Neoral (Ciclosporin)

Ciclosporin binds to cyclophilin inside immune cells, forming a complex that inhibits calcineurin. This inhibition blocks the activation of nuclear factor of activated T‑cells, reducing interleukin‑2 production and T‑cell proliferation, which lowers the overall immune activity.

The dosage of Neoral is individualized. A qualified prescriber determines the appropriate amount based on the patient’s condition, weight, organ function and other medications. Specific dosing regimens are not disclosed publicly and must be obtained from a healthcare professional.

Ciclosporin’s pregnancy category is not clearly defined, and it may cross the placenta. Use during pregnancy or lactation should only occur when the potential benefit justifies the potential risk. Patients should discuss their situation with a physician before using Neoral while pregnant or nursing.

To order Neoral, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to ciclosporin is tacrolimus, another calcineurin inhibitor. Both suppress T‑cell activation, but tacrolimus is often considered more potent with a different side‑effect profile, such as a higher incidence of neurotoxicity. Choice between them depends on clinical response, tolerance and physician preference.

Neoral oral solution should be stored at ambient temperature, preferably below 25 °C. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing. If the solution appears discolored or contains particles, it should not be used.

Neoral is taken orally as a measured dose of the liquid solution. The dose should be measured with a calibrated syringe or dosing cup, taken consistently at the same times each day, and may be taken with or without food as directed by the prescriber.

Serious risks include nephrotoxicity (decline in kidney function), heightened susceptibility to infections, hypertension, liver enzyme elevations, and a potential increased risk of malignancies with long‑term use. Patients should be monitored regularly for these complications.

Neoral is contraindicated in individuals with known hypersensitivity to ciclosporin or any formulation components, those with uncontrolled infections, severe renal impairment, or uncontrolled hypertension. It should also be avoided in patients receiving certain interacting drugs without close medical supervision.